Trial Profile
Safety and efficacy of Glecaprevir/Pibrentasvir combination therapy for chronic hepatitis C - including hemodialysis patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 Apr 2022 Status changed from active, no longer recruiting to completed.
- 14 Oct 2019 Results published in the Journal of Gastroenterology and Hepatology.
- 12 Oct 2019 Status changed from recruiting to active, no longer recruiting.